Japan pledges $200 million GHIT Fund's third phase of operations

25 May 2023

Prime Minister Fumio Kishida has announced the government of Japan's pledge to contribute $200 million to the Global Health Innovative Technology Fund (GHIT Fund).

This fund is an international public-private partnership between the Japanese government, seven Japanese pharma and diagnostics firms comprising of Astellas (TYO: 4503), Chugai, Eisai (TYO: 4523), Daiichi Sankyo (TYO: 4568), Shionogi (TYO: 4507), Sysmex (TYO: 6869) and Takeda (TYO: 4502), the Bill & Melinda Gates Foundation, Wellcome Trust, and the United Nations Development Program.

Japan’s latest pledge, announced at the G7 Hiroshima Summit 2023, supports the GHIT Fund’s third phase of operations, including investments in research and development of drugs, vaccines and diagnostics, using the country’s innovation and expertise to prevent and address infectious diseases such as tuberculosis, malaria and neglected tropical diseases, which are highly prevalent in low- and middle-income countries.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK